Key Highlights

  • Liquidia Corporation (NASDAQ:LQDA) climbed 64.79% over a month to USD 46.06 after settling six lawsuits with United Therapeutics on October 14, 2026, with about USD 380.7 million in net payments due through April 2027.
  • Viridian Therapeutics (NASDAQ:VRDN) advanced 50.84% to USD 28.66 and 17.7% on the week, as first Lumvoa net product Revenue of USD 24.7 million and cash of USD 955.2 million came into view.
  • Hemab Therapeutics Holdings (NASDAQ:COAG) rose 43.77% to USD 44.30 without an identified catalyst, sitting 146% above its USD 18 IPO price by calculation.
  • All three rank among the best performing mid caps of USD 2 billion to USD 10 billion in a published screener snapshot, yet Liquidia's three month change is negative 48.79% and Hemab's is negative 15.64%.

Liquidia Corporation (NASDAQ:LQDA): Settlement Lifts Shares 64.79% After a Court Setback

A settlement is the fulcrum of this rebound, and it followed a court setback. On September 30, 2026, a Delaware court concluded that YUTREPIA infringed two claims of a United Therapeutics Patent covering inhaled treprostinil for PH-ILD, while rejecting four other asserted claims as invalid. The shares lost roughly 57% that day and then about 14% more, falling to a level near USD 26.60. On October 14, 2026, the company resolved the six pending suits and gained about 40% in that session. Liquidia Corporation (NASDAQ:LQDA) must take the PH-ILD indication off its label but may keep selling YUTREPIA for PAH, with net payments of roughly USD 380.7 million through April 2027, the first USD 175 million due within 30 Business days. Settlements remove an open ended injunction threat, which is why such stocks can re-rate. LifeSci Capital moved to Outperform with a USD 59 target, and Wells Fargo raised its target to USD 33 from USD 30. Preliminary third quarter YUTREPIA sales reached USD 222.7 million against USD 170.4 million in the second quarter, and cash stood at USD 396.1 million at September 30, 2026. BTIG upgraded the shares to Buy with a USD 70 target, while Needham trimmed its target to USD 58 from USD 72. At USD 46.06 the stock is up 64.79% on the month, yet it is still down 48.79% over three months and up 9.56% over six, so the earlier decline has not fully reversed. Management expects to fund the payments from cash and revenue, and second quarter revenue of USD 171.7 million alongside Net Income of USD 74.7 million gives context. The risks are the cash outflow, a possible appeal, the narrower label and open questions about pipeline legal matters around L606.

Viridian Therapeutics (NASDAQ:VRDN): Launch Revenue Behind a 50.84% Monthly Climb

The clearest documented driver is a product launch. The Quarterly Report for the period ended September 30, 2026 shows the first product revenue after the FDA cleared veligrotug, sold as Lumvoa for thyroid eye disease, in June 2026: USD 24.7 million of net product revenue and USD 25.8 million of total revenue. Viridian Therapeutics (NASDAQ:VRDN) trades at USD 28.66, up 50.84% over a month, 17.7% over a week, 24.72% over three months and 68.59% over six. First sales often re-rate a biotech because investors can measure revenue against spending, and here the quarterly net loss of USD 101.2 million is about four times net revenue, a simple arithmetic result from two published figures. Other items include a review pending at the EMA, a planned elegrobart BLA in the first quarter of 2027 and a Phase 1 start for VRDN-292 in Graves' disease. Nothing specific to the past week was identified, which makes the 17.7% weekly gain general context. Cash and marketable securities were USD 955.2 million, but nine month operating spending of USD 370.6 million (calculated) points to continued burn and possible dilution across 113.6 million shares. Research and Development cost USD 70.1 million in the quarter and selling, general and administrative cost USD 57.6 million, a heavy base against USD 24.7 million of product revenue. Launch metrics may disappoint, state distribution licenses are still pending and a temporary title model is in use, so the 68.59% six month gain already sets high expectations.

Hemab Therapeutics Holdings (NASDAQ:COAG): Gains Without a Named Catalyst After a Recent IPO

No trigger could be identified for the month, and the material reviewed lists no Earnings release, trial data or filing inside the window. Hemab Therapeutics Holdings (NASDAQ:COAG) is quoted at USD 44.30, up 43.77% over a month and 13.90% over a week, although three month performance is negative 15.64% and six month performance is 72.09%. Generally speaking, young biotechs can rise when research coverage starts after quiet periods, when healthcare sector rotation favors smaller names, or when a limited float after an offering tightens supply, but none of these is confirmed as a cause here. The IPO priced on April 30, 2026 at USD 18 per share, offering 16.8 million shares, upsized from 11.8 million, for about USD 302 million raised. The stock listed after pricing at the top of a USD 16 to USD 18 range, with Goldman Sachs, Jefferies and Evercore ISI as joint bookrunners. The firmer ground is the pipeline: sutacimig, a subcutaneous bispecific antibody for Glanzmann thrombasthenia, received FDA Breakthrough Therapy Designation in March 2026, and HMB-002 is in Phase 1/2 for von Willebrand disease. A published release put the first day close at nearly 90% above the offer, and the current price sits 146% above the offer by calculation, so much of the premium predates this month. With no commercial revenue in the figures reviewed, price to sales and P/E ratios are not meaningful, and valuation rests on the pipeline. A recent IPO may carry a modest public float, a few trades can move the price, and clinical setbacks, a delay to Phase 3, financing needs and lock-up expirations are the specific risks.

Where Things Stand

Liquidia Corporation (NASDAQ:LQDA) led the group at 64.79%, and a settlement that ended its patent dispute is the direct answer to why the shares rose. Viridian (NASDAQ:VRDN) followed at 50.84%, tied to launch sales. Hemab (NASDAQ:COAG) was up 43.77% with no named catalyst. Each of the three is a biotech Mid cap of USD 2 billion to USD 10 billion, per a published screener snapshot of November 5, 2026, and each price depends on one product or pipeline. Rallies of this size can reverse when trading is thin, spreads widen and expectations are already high. This is context, not advice.